Zika Virus Market Spotlight 2019: Key Pipeline Therapies, Clinical Trials, and Licensing and Acquisition Deals – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Market
Spotlight: Zika Virus” report has been added to ResearchAndMarkets.com’s
offering.

This Market Spotlight report covers the Zika virus market, comprising
key pipeline therapies, clinical trials, and licensing and acquisition
deals.

Key Takeaways

• The Zika virus was first reported in continental South America in
  Brazil in May 2015. In February 2016, between 440,000 and 1,300,000
  people were infected in Brazil. In the US, about 225 Zika virus cases
  were reported in August 2017. In addition, 554 cases were reported in
  people infected through local mosquito-borne transmission.
  Furthermore, autochthonous Zika virus transmission was reported in 25
  countries in the Americas, Africa, and Asia.
• In 2016, it was estimated that there were between 508 and 1,778
  imported cases in Europe, particularly in France, Portugal, and Italy.
• The majority of industry-sponsored drugs in active clinical
  development for Zika virus are in Phase I, with just a single product
  in Phase II.
• Therapies in early-to-mid-stage development for Zika virus focus on
  the immune system and viral antigens. Candidates comprise DNA vaccines
  such as the National Institutes of Health’s Zika Virus Vaccine,
  GeneOne’s GLS-5700, and Inovio’s INO-A002; Moderna’s mRNA vaccine;
  Themis Bioscience’s recombinant viral vector vaccine; Imutex’s AGS-v
  vaccine; Johnson & Johnson’s Ad26.ZIKV.001 vaccine; Takeda’s TAK-426
  vaccine; Emergent BioSolutions’ ZIKV-IG; and Valneva’s ZIKV-VLA1601.
• The overall likelihood of approval of a Phase I antiviral asset is
  16.2%, and the average probability a drug advances from Phase III is
  75.9%. Drugs, on average, take 8.6 years from Phase I to approval,
  compared to 9.0 years in the overall infectious disease space.
• There have been 10 licensing and asset acquisition deals involving
  Zika virus drugs during 2014-19, all of which occurred in either 2016
  or 2017. The exclusive 2017 agreement between Emergent BioSolutions
  and Valneva worth $58.3m for the global rights to Valneva’s Zika
  vaccine technology and ZIKV-VLA1601 was the largest deal.
• The distribution of clinical trials across Phase I-IV indicates that
  the majority of trials for Zika virus have been in Phase I.
• The US leads the number of Zika virus clinical trials globally. The
  largest share of industry-sponsored clinical trials are ongoing.
  Takeda and GeoVax have planned one trial each in the Zika virus space.
• Sanofi leads industry sponsors with three clinical trials for Zika
  virus, although all of its trials have been terminated.

Key Topics Covered:

OVERVIEW

KEY TAKEAWAYS

DISEASE BACKGROUND

TREATMENT

Vaccines

Therapeutics

EPIDEMIOLOGY

PIPELINE DRUGS

PROBABILITY OF SUCCESS

LICENSING AND ASSET ACQUISITION DEALS

GeoVax Collaborates With Enesi Pharma On Needle-Free Vaccines

Bridging The Gap: Cyclenium Pharma

Brazil’s Oneway Diagnostica, iBio Collaborate On Virus Diagnostics

CLINICAL TRIAL LANDSCAPE

Sponsors by status

Sponsors by phase

Recent events

BIBLIOGRAPHY

APPENDIX

LIST OF FIGURES

For more information about this report visit https://www.researchandmarkets.com/r/royn7g

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Infectious
Diseases Drugs